Breaking News Instant updates and real-time market news.

NKTR

Nektar

$39.99

0.98 (2.51%)

09:03
11/06/18
11/06
09:03
11/06/18
09:03

Nektar abstract references old 50% ORR, says Piper Jaffray

The regular Society for Immunotherapy of Cancer abstract that provides an update of the first line melanoma patient cohort in the ongoing PIVOT-02 trial testing the combination of Nektar Therapeutics's NKTR-214 plus Opdivo was posted, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that 41 patients were enrolled with 38 evaluable for efficacy and the investigator-assessed objective response rate as of July 12 was 50%. Van Buren says that while is this is what we already knew, it confirms his prior assumption of the 50% response rate floor heading into the Friday afternoon updated data presentation. On Friday, the analyst expects to receive an updated response rate and more details on the quality of response. Finally, no responder has relapsed in this cohort and median duration of response has not been reached, which is promising as we begin to think about the probability of success for the Phase III trial, says the analyst. Shares of Nektar are down 7%, or $2.75, to $37.25 in pre-market trading.

  • 07

    Nov

  • 07

    Nov

  • 10

    Nov

  • 12

    Nov

  • 27

    Nov

NKTR Nektar
$39.99

0.98 (2.51%)

08/08/18
PIPR
08/08/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar offered more 'granularity' on PIVOT data timing, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $125 price target on Nektar after its Q2 earnings beat, saying the management has also offered more detail on the company's data release plans. The analyst sees the 1L melanoma cohort readout coming before the end of 2018, followed by RCC and bladder cancer data likely in the first half of 2019 and other tumor types later next year. Van Buren adds that these disclosures should hopefully add to the company's understanding about the efficacy of 214+nivo combination therapy.
08/09/18
MZHO
08/09/18
NO CHANGE
Target $103
MZHO
Buy
Nektar to report additional data in coming months, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with a $103 price target following last night's Q2 results. Data readouts of NKTR-214 remain the main catalyst for the shares, Yang tells investors in a research note. She points out that management expects to present data at a number of conferences in the coming months, including melanoma data at the Society for Immunotherapy of Cancer on November 7-11. While details on additional data in other indications "were sparse," data should be announced over the coming six-to-eight months, Yang contends.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."

TODAY'S FREE FLY STORIES

TSLA

Tesla

$305.56

-2.2 (-0.71%)

19:17
02/19/19
02/19
19:17
02/19/19
19:17
Hot Stocks
Tesla CEO says company will make about 500,000 cars in 2019 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

IDCC

InterDigital

$73.13

-0.26 (-0.35%)

19:06
02/19/19
02/19
19:06
02/19/19
19:06
Hot Stocks
InterDigital says LG Electronics extends license to use Hillcrest's Freespace »

InterDigital, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

TWTR

Twitter

$31.64

0.41 (1.31%)

19:03
02/19/19
02/19
19:03
02/19/19
19:03
Hot Stocks
Tesla CEO says 4,000 cars loading in San Francisco for Europe »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

OSPN

OneSpan

$16.78

0.645 (4.00%)

, HSTM

HealthStream

$26.95

0.09 (0.34%)

19:01
02/19/19
02/19
19:01
02/19/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

OSPN

OneSpan

$16.78

0.645 (4.00%)

HSTM

HealthStream

$26.95

0.09 (0.34%)

LNTH

Lantheus

$19.18

0.67 (3.62%)

CDNS

Cadence Design

$52.65

0.09 (0.17%)

CRMT

America's Car-Mart

$81.74

-0.43 (-0.52%)

DVN

Devon Energy

$28.31

-0.11 (-0.39%)

LMAT

LeMaitre

$25.09

-0.01 (-0.04%)

FIVN

Five9

$54.31

0.1 (0.18%)

NVTA

Invitae

$16.49

0.43 (2.68%)

LZB

La-Z-Boy

$32.23

0.845 (2.69%)

DK

Delek US

$34.87

0.025 (0.07%)

VRSK

Verisk Analytics

$124.45

-0.93 (-0.74%)

WIRE

Encore Wire

$56.32

1.32 (2.40%)

HLF

Herbalife Nutrition

$57.46

0.8 (1.41%)

TVTY

Tivity Health

$21.67

0.28 (1.31%)

IIN

IntriCon

$29.43

2 (7.29%)

LC

LendingClub

$3.62

0.05 (1.40%)

CXO

Concho Resources

$120.95

-2.03 (-1.65%)

FANG

Diamondback Energy

$104.75

-0.78 (-0.74%)

TXRH

Texas Roadhouse

$65.58

0.03 (0.05%)

SSTI

ShotSpotter

$48.18

2.2 (4.78%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 04

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 28

    Mar

  • 22

    May

  • 28

    May

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:58
02/19/19
02/19
18:58
02/19/19
18:58
Hot Stocks
Hudbay Minerals announces increased reserves at Lalor mine »

Hudbay Minerals announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:56
02/19/19
02/19
18:56
02/19/19
18:56
Hot Stocks
Hudbay Minerals reports Q4 copper output 37.2K tonnes, down 14% from last year »

Reports Q4 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CLXT

Calyxt

$13.56

0.15 (1.12%)

18:55
02/19/19
02/19
18:55
02/19/19
18:55
Hot Stocks
Calyxt, Agtegra Cooperative announce strategic collaboration »

Calyxt and Agtegra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:54
02/19/19
02/19
18:54
02/19/19
18:54
Earnings
Hudbay Minerals reports Q4 EPS (1c), consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOC

Northrop Grumman

$287.36

0.44 (0.15%)

18:39
02/19/19
02/19
18:39
02/19/19
18:39
Hot Stocks
Northrop Grumman recommends shareholders to reject offer by TRC Capital »

Northrop Grumman has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

18:31
02/19/19
02/19
18:31
02/19/19
18:31
Periodicals
POTUS says U.S. corn sales to China part of trade talks, Bloomberg says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$9.69

0.11 (1.15%)

18:29
02/19/19
02/19
18:29
02/19/19
18:29
Hot Stocks
Aphria announces early termination of Liberty Health Sciences divestment »

Aphria announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.01

0.02 (0.11%)

, AGN

Allergan

$137.94

-1.13 (-0.81%)

18:26
02/19/19
02/19
18:26
02/19/19
18:26
Hot Stocks
Teva finalizes settlement with FTC to resolve all outstanding litigation »

Teva Pharmaceutical…

TEVA

Teva

$18.01

0.02 (0.11%)

AGN

Allergan

$137.94

-1.13 (-0.81%)

ABBV

AbbVie

$80.50

-0.35 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 18

    May

  • 28

    May

18:25
02/19/19
02/19
18:25
02/19/19
18:25
Conference/Events
CLSA technology analyst to hold an analyst/industry conference call »

Technology Sales…

VICL

Vical

$1.01

(0.00%)

18:19
02/19/19
02/19
18:19
02/19/19
18:19
Hot Stocks
Breaking Hot Stocks news story on Vical »

Vical resumes trade down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$57.39

0.5847 (1.03%)

, MDLZ

Mondelez

$48.10

-0.07 (-0.15%)

18:19
02/19/19
02/19
18:19
02/19/19
18:19
Periodicals
Kellogg, Mondelez stock up on snacks as Brexit looms, Reuters reports »

With Brexit on the…

K

Kellogg

$57.39

0.5847 (1.03%)

MDLZ

Mondelez

$48.10

-0.07 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 03

    Mar

  • 06

    Mar

  • 28

    May

OMI

Owens & Minor

$7.94

0.25 (3.25%)

18:19
02/19/19
02/19
18:19
02/19/19
18:19
Earnings
Owens & Minor guides initial FY19 EPS 60c-75c, consensus $1.02 »

"2019 is about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$7.94

0.25 (3.25%)

18:17
02/19/19
02/19
18:17
02/19/19
18:17
Earnings
Owens & Minor reports Q4 adjusted EPS 9c, consensus 13c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

USAC

USA Compression

$15.61

0.61 (4.07%)

18:15
02/19/19
02/19
18:15
02/19/19
18:15
Recommendations
USA Compression analyst commentary  »

USA Compression Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

DK

Delek US

$34.87

0.025 (0.07%)

18:04
02/19/19
02/19
18:04
02/19/19
18:04
Hot Stocks
Delek US raises dividend 3.8% to 27c »

Delek US announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

DK

Delek US

$34.87

0.025 (0.07%)

18:03
02/19/19
02/19
18:03
02/19/19
18:03
Earnings
Delek US reports Q4 adjusted EPS $1.59, consensus $1.25 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

DKL

Delek Logistics

$30.39

0.58 (1.95%)

18:01
02/19/19
02/19
18:01
02/19/19
18:01
Earnings
Delek Logistics reports Q4 EPS 58c, consensus 74c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$7.94

0.25 (3.25%)

, TMO

Thermo Fisher

$250.77

-1.615 (-0.64%)

17:49
02/19/19
02/19
17:49
02/19/19
17:49
Hot Stocks
Owens & Minor names Ed Pesicka President and CEO »

Owens & Minor (OMI)…

OMI

Owens & Minor

$7.94

0.25 (3.25%)

TMO

Thermo Fisher

$250.77

-1.615 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

VICL

Vical

$1.01

(0.00%)

17:49
02/19/19
02/19
17:49
02/19/19
17:49
Hot Stocks
Breaking Hot Stocks news story on Vical »

Vical to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.01

(0.00%)

17:48
02/19/19
02/19
17:48
02/19/19
17:48
Earnings
Vical reports Q4 EPS (17c), two estimates (17c) »

Vical had cash and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.01

(0.00%)

17:46
02/19/19
02/19
17:46
02/19/19
17:46
Hot Stocks
Vical to discontinue development of VL-2397, to consider strategic options »

Vical Incorporated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.